- Andrew Frankel
Imperial College Healthcare NHS
Dr Andrew Frankel has been working as a consultant nephrologist at Imperial College Healthcare NHS trust since 1995. He has experience in managing all aspects of kidney disease but has a particular interest in relation to the management of diabetes in the context of kidney disease. Over the years he has maintained a significant research interest in relation to diabetes and kidney, both in terms of how diabetes affects the kidneys leading to deterioration in kidney function, but also in relation to how the presence of kidney disease influences the management of diabetes. Because of this experience, Dr Frankel has played a significant role in the development of national guidelines on the management of diabetes in the context of kidney disease. He is a regular speaker both locally and nationally and indeed internationally in relation to matters pertaining to diabetes and the kidney.
In collaboration with colleagues within Imperial College and indeed both nationally and internationally, Dr Frankel has published research in relation to assessment of renal complications in patients with diabetes and obesity. He is active in clinical research and maintains a number of ongoing research studies.
Dr Frankel has significant commitment to and experience in relation to training the next generation of doctors, having been the director Imperial’s Foundation School from its inception to 2010, London lead for Foundation Training and Postgraduate Dean for south London from 2013 and 2018.
- Not accredited
- Explain the relationship between sub-optimal RAASi therapy and poor cardio-renal outcomes
- Identify patients who would benefit from anti-hyperkalaemia medications
- Select appropriate anti-hyperkalaemia treatments across a range of patient profiles
- Adopt anti-hyperkalaemia medications as an approach to prolong optimal RAASi therapy
- Summarise current guideline recommendations on the use of potassium binding agents